GLP-1 / Weight Loss

Semaglutide Review: Ozempic and Wegovy Assessed Independently

Semaglutide is the most evidence-backed weight loss medication in history, with ~15% average weight loss and significant cardiovascular benefits demonstrated in large-scale trials. The primary limitations are cost, GI side effects during titration, and the requirement for ongoing use to maintain results.

Overall Rating

9/10

Rating Breakdown

Evidence Quality
10/10
Side Effect Profile
7/10
Value for Money
6/10
Ease of Use
8/10
User Satisfaction
9/10
Overall
9/10

Pros & Cons

Pros
  • Most extensively studied weight loss medication ever — STEP and SELECT trials
  • ~15% average weight loss (Wegovy dose) — unprecedented for a medication
  • 20% cardiovascular risk reduction in non-diabetic obese patients (SELECT trial)
  • Once-weekly injection — highly convenient
  • FDA approved for both diabetes (Ozempic) and obesity (Wegovy)
  • Durable weight loss with continued use
Cons
  • Nausea, vomiting, and GI side effects during titration (affects ~40% of users)
  • High cost — ~$900-$1,000/month without insurance
  • Weight regain after discontinuation (most users regain weight)
  • Requires ongoing use to maintain results
  • Rare but serious: pancreatitis, thyroid C-cell tumors (animal data)
  • Muscle loss with rapid weight reduction (mitigated by protein intake and resistance training)
Who Should Consider

Adults with BMI ≥30 (or ≥27 with weight-related comorbidities); people with type 2 diabetes seeking both glycemic control and weight loss; those with cardiovascular disease risk who would benefit from the SELECT trial's demonstrated CV risk reduction.

Who Should Avoid

Personal or family history of medullary thyroid carcinoma or MEN2; history of pancreatitis; pregnancy; those who cannot afford ongoing treatment without insurance coverage.

Our Verdict

Semaglutide represents a genuine paradigm shift in obesity treatment. The clinical evidence is extraordinary — ~15% average weight loss and 20% cardiovascular risk reduction are outcomes that no previous obesity medication has achieved. The limitations are real: GI side effects during titration, high cost, and the need for ongoing use. But for appropriate candidates, semaglutide is the most evidence-backed tool available for significant, sustained weight loss.

Frequently Asked Questions

How much weight can I lose on semaglutide?

Clinical trials show ~15% average body weight loss at the Wegovy dose (2.4mg weekly). Individual results vary — some lose more, some less. Maximum weight loss typically occurs at 60-68 weeks.

What happens when you stop taking semaglutide?

Most people regain the majority of lost weight within 1-2 years of stopping. Semaglutide treats obesity as a chronic condition requiring ongoing treatment, similar to blood pressure medication.

Is Ozempic the same as Wegovy?

Both contain semaglutide, but at different doses. Ozempic is approved for type 2 diabetes (up to 1mg weekly); Wegovy is approved for obesity (up to 2.4mg weekly). The higher Wegovy dose produces greater weight loss.

Alternatives to Consider

Is Semaglutide (Ozempic / Wegovy) right for your biology?

Take our 5-minute quiz to get a personalized peptide recommendation based on your specific goals and health profile.